GB201508380D0 - Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia - Google Patents

Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia

Info

Publication number
GB201508380D0
GB201508380D0 GBGB1508380.1A GB201508380A GB201508380D0 GB 201508380 D0 GB201508380 D0 GB 201508380D0 GB 201508380 A GB201508380 A GB 201508380A GB 201508380 D0 GB201508380 D0 GB 201508380D0
Authority
GB
United Kingdom
Prior art keywords
prognosis
diagnosis
determining
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1508380.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nodality Inc
Original Assignee
Nodality Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nodality Inc filed Critical Nodality Inc
Publication of GB201508380D0 publication Critical patent/GB201508380D0/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1508380.1A 2009-10-22 2015-05-15 Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia Ceased GB201508380D0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25413109P 2009-10-22 2009-10-22
US26558509P 2009-12-01 2009-12-01
US26574309P 2009-12-01 2009-12-01
US35086410P 2010-06-02 2010-06-02
US37319910P 2010-08-12 2010-08-12
US37461310P 2010-08-18 2010-08-18
US38279310P 2010-09-14 2010-09-14

Publications (1)

Publication Number Publication Date
GB201508380D0 true GB201508380D0 (en) 2015-07-01

Family

ID=43334232

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1017857A Withdrawn GB2474777A (en) 2009-10-22 2010-10-22 Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia
GBGB1508380.1A Ceased GB201508380D0 (en) 2009-10-22 2015-05-15 Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB1017857A Withdrawn GB2474777A (en) 2009-10-22 2010-10-22 Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia

Country Status (1)

Country Link
GB (2) GB2474777A (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025847A2 (en) * 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20090291458A1 (en) * 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
EP2304436A1 (en) * 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
WO2010135608A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Also Published As

Publication number Publication date
GB201017857D0 (en) 2010-12-01
GB2474777A (en) 2011-04-27

Similar Documents

Publication Publication Date Title
EP2179037A4 (en) Methods for diagnosis, prognosis and methods of treatment
GB0906458D0 (en) Macromolecules for diagnosis and prognosis
EP2323677A4 (en) Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
HK1187377A1 (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2257647A4 (en) MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
HK1208501A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
HK1199754A1 (en) Method for monitoring, diagnosis and or prognosis of acute kidney injury in early stage
EP2652506A4 (en) The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer
IL212898A0 (en) Processing blood
IL247324A0 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2011008262A9 (en) Methods and apparatus for diagnosis and/or prognosis of cancer
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
AP2011005824A0 (en) Methods for treating acute myocardial infarctions and associated disorders.
PT3029156T (en) Method for the diagnosis and/or prognosis of acute renal damage
EP2393416A4 (en) Methods and apparatuses for quantitatively determining the likelihood of a disease
EP2657706A4 (en) Biomarker for cognitive dysfunction diseases, and method for detection of cognitive dysfunction diseases using the biomarker
EP2652508A4 (en) The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
EP2402744A4 (en) Carburization detection method
HK1184199A1 (en) Biosensor test member and method for making the same
EP2888370A4 (en) Methods for diagnosis, prognosis and methods of treatment
EP2016172A4 (en) Diagnostic methods for determining treatment
EP2493494A4 (en) Methods and kits for preventing hypoglycemia
BRPI0822129A2 (en) Aldh-2c inhibitors in the treatment of addiction.
HK1174955A1 (en) Detecting pax2 for the diagnosis of breast cancer pax2

Legal Events

Date Code Title Description
R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20160101

Free format text: EXTENSION APPLICATION

Effective date: 20150911

AT Applications terminated before publication under section 16(1)